Tempus AI, a technology company advancing precision medicine through the practical application of AI, announced a new collaboration with Bristol Myers Squibb on May 14th, 2026. The new initiative aims to optimize clinical trial design and enhance the probability of technical and regulatory success via application of AI, multimodal real-world data, and data science techniques, according to a company press release.
According to the release, Tempus’ analytical platform Lens will be used to apply insights from a library of de-identified multimodal records. The new initiative, which encompasses five initial clinical trial programs, will support various assets in solid tumor oncology, including lung, colon, and prostate cancers, as well as drug development for Alzheimer’s Disease.
“Our collaboration with MS aims to optimize clinical development by peering deeper into patient biology than ever before,” said Ryan Fukushima, CEO of Data and Apps, Tempus, in the release. “Our multimodal data library allows us to connect the dots between clinical records and molecular subtypes. Together, we are doing more than just generating insights. We are uncovering the hidden biological signals of unmet patient need, which allows us to assess trial assumptions and stratify patient groups with unprecedented precision. We are moving past traditional approaches and creating a new level of data-driven confidence in the drug development process.”
“This collaboration is about improving the quality of decisions we make in development, where the impact is greatest,” said Bryan Campbell, Senior Vice President, Drug Development Strategy & Innovation, Bristol Myers Squibb, in the release. “By combining Tempus’ multimodal real-world data capabilities with our development expertise, we can rigorously pressure-test trial assumptions, better understand patient heterogeneity, and design studies with a higher probability of technical and regulatory success. This is a critical step toward more disciplined, data-driven development with the goal of bringing life-changing medicines to patients faster.”
Tempus and BMS previously worked together to deploy the Next Pathways program across 13 community-based health systems to address care gaps for patients with advanced non-small cell lung cancer, according to the release. Financial terms of the agreement were not disclosed in the press release announcing the initiative.
